RRoche Read More What Could Roche Holding (SWX:ROP) Gain From FDA Priority Review In MS?2026-10-19 Roche Holding (SWX:ROP) received FDA acceptance of its New Drug Application for fenebrutinib in multiple sclerosis under priority…
RRoche Read More Roche’s Fenebrutinib Receives FDA Priority Review for Relapsing and Primary Progressive Multiple Sclerosis2026-09-30 Researcher with pipette ©National Institutes of Health The FDA has accepted fenebrutinib for priority review across two forms…
BBern Read More More than 1,200 cyclists ride through New Bern for annual Bike MS event2026-09-19 The above video is our WITN+ livestream and may not reflect the content in this story. NEW BERN,…
NNovartis Read More Novartis Stock Prices Rise After Positive Multiple Sclerosis Drug Trial Results2026-09-14 Novartis NOVN -0.09%decrease; down pointing triangle shares rose after the drugmaker reported positive results from two late-stage trials…
NNovartis Read More StockWatch: Novartis Loses More than Market Value After Phase III Failure2026-09-14 A Novartis researcher at work. Novartis saw some of its top investors publicly express dissatisfaction with its direction…
NNovartis Read More Could Remibrutinib Become the Next $9 Billion Drug for Novartis?2026-09-11 Novartis AG (NYSE:NVS) has reported the first major success from three closely watched pipeline programs expected to produce…
RRoche Read More Roche gets Phase 3 trial waiver for higher dose of multiple sclerosis drug | Industry News2026-09-04 CDSCO expert panel grants waiver for 920 mg Ocrelizumab, subject to Roche conducting a Phase 4 clinical trial…
RRoche Read More Roche gets Phase 3 trial waiver for higher dose of multiple sclerosis drug | Industry News2026-09-04 Global pharma major Roche has been given a Phase 3 trial waiver for a higher dosage form of…
NNovartis Read More Novartis’ Remibrutinib Delivers Positive Results in Late-Stage MS Studies2026-09-02 Novartis NVS announced positive top-line results from the late-stage REMODEL-1/-2 studies on remibrutinib in relapsing multiple sclerosis (RMS).…
NNovartis Read More Will Patient Deaths Derail the CAR-T Train in Autoimmune Disease?2026-09-02 Two Big Pharma companies have reportedly paused their ongoing trials of chimeric antigen receptor (CAR) T-cell therapies in…
NNovartis Read More Novartis’ Remibrutinib Shows Superior Efficacy in MS Trials, Outshining Older Treatment, ETPharma2026-09-02 London: Swiss drugmaker Novartis said on Tuesday its oral drug remibrutinib outperformed an older treatment in reducing relapses…
NNovartis Read More Novartis pauses 8 cell therapy trials after three die due to severe immune reaction2026-09-02 Following the death of three patients who were part of an experimental cell therapy called rap-cel, Novartis decided…